Increased Expression of a Disintegrin and Metalloprotease-9 in Hepatocellular Carcinoma: Implications for Tumor Progression and Prognosis
Open Access
- 13 April 2010
- journal article
- research article
- Published by Oxford University Press (OUP) in Japanese Journal of Clinical Oncology
- Vol. 40 (7), 645-651
- https://doi.org/10.1093/jjco/hyq030
Abstract
A disintegrin and metalloprotease-9 has been involved in the carcinogenesis of various solid tumors. However, its role in hepatocellular carcinoma remains unknown. The aim of this study was to investigate the clinicopathological and prognostic relevance of a disintegrin and metalloprotease-9 by immunohistochemistry. The expression profile of a disintegrin and metalloprotease-9 in association with the clinicopathological factors was determined by immunohistochemical analysis in hepatocellular carcinoma patients, and its potential prognostic value was investigated by comparing the survival rate between a disintegrin and metalloprotease-9-positive and a disintegrin and metalloprotease-9-negative patients. Hepatocellular carcinoma tissues with positive a disintegrin and metalloprotease-9 expression were larger and less differentiated than those with negative expression (P = 0.02 and 0.008, respectively). Portal venous invasion, hepatic venous invasion, bile duct invasion and intrahepatic metastasis were detected significantly more frequently in a disintegrin and metalloprotease-9-positive group (P = 0.009, 0.01, 0.03 and 0.02, respectively). In addition, high α-fetoprotein levels were significantly associated with the expression of a disintegrin and metalloprotease-9 in hepatocellular carcinoma (P = 0.01). Moreover, a disintegrin and metalloprotease-9-positive group had significantly poorer outcomes than a disintegrin and metalloprotease-9-negative group (P = 0.01) and was an independent prognostic factor for overall survival. A disintegrin and metalloprotease-9 is over-expressed in hepatocellular carcinoma tissues, consistent with findings in other tumor entities, and is an independent prognostic marker of overall survival following hepatectomy. Further studies are needed to investigate the precise function of a disintegrin and metalloprotease-9 in the progression of hepatocellular carcinoma.Keywords
This publication has 24 references indexed in Scilit:
- Oral contraception and the risk of hepatocellular carcinomaJournal of Hepatology, 2007
- Hepatocellular carcinoma pathogenesis: from genes to environmentNature Reviews Cancer, 2006
- Epigenetic gene silencing in cancer – a mechanism for early oncogenic pathway addiction?Nature Reviews Cancer, 2006
- Critical Function for ADAM9 in Mouse Prostate CancerCancer Research, 2005
- The ErbB Receptors and their Ligands in Cancer: An OverviewCurrent Drug Targets, 2005
- Overexpression of ADAM9 in Non-Small Cell Lung Cancer Correlates with Brain MetastasisCancer Research, 2004
- Expression of ADAM‐9 mRNA and protein in human breast cancerInternational Journal of Cancer, 2003
- Exploration of Global Gene Expression Patterns in Pancreatic Adenocarcinoma Using cDNA MicroarraysThe American Journal of Pathology, 2003
- The ADAMs family of metalloproteases: multidomain proteins with multiple functionsGenes & Development, 2003
- Molecular pathogenesis of human hepatocellular carcinomaNature Genetics, 2002